Drug Type Monoclonal antibody |
Synonyms ATRC 101, MATRC-101 |
Target |
Mechanism RNP inhibitors(RNA binding region (RNP1, RRM) containing 3 inhibitors) |
Therapeutic Areas |
Active Indication- |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhaseDiscontinuedPhase 1 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Acral Lentiginous Malignant Melanoma | Phase 1 | US | 11 Feb 2020 | |
Advanced Malignant Solid Neoplasm | Phase 1 | US | 11 Feb 2020 | |
Esophageal Squamous Cell Carcinoma | Phase 1 | US | 11 Feb 2020 | |
Hepatocellular Carcinoma | Phase 1 | US | 11 Feb 2020 | |
Microsatellite instability-high colorectal cancer | Phase 1 | US | 11 Feb 2020 | |
Non-Small Cell Lung Cancer | Phase 1 | US | 11 Feb 2020 | |
Platinum-Resistant Epithelial Ovarian Carcinoma | Phase 1 | US | 11 Feb 2020 | |
Platinum-Resistant Fallopian Tube Carcinoma | Phase 1 | US | 11 Feb 2020 | |
Platinum-Resistant Primary Peritoneal Carcinoma | Phase 1 | US | 11 Feb 2020 | |
Squamous Cell Carcinoma of Head and Neck | Phase 1 | US | 11 Feb 2020 |
NCT04244552 (ASCO2023) Manual | Phase 1 | 67 | cwphnibsrt(dqfhxztvbq) = xfptrlzual hhjpqxjpjf (atktaessxq ) View more | Positive | 31 May 2023 | ||
Phase 1 | 26 | hcrzhxhhjk(jbhkcqwstq) = squbjbjapq ubcaxiqacj (zcxhxigisg ) View more | Positive | 29 Jul 2021 |